ADC & Bioconjugate Development Services
Our site-specific conjugation services support the development of optimized antibody-drug conjugates (ADCs) and bioconjugates, helping advance programs through efficient conjugation development, process optimization, and analytical characterization.
Powered by AJICAP™ Site-Specific Conjugation Technology
At the core of our site-specific conjugation services is AJICAP™, our proprietary site-specific antibody conjugation and linker technology, enabling precise payload attachment to native antibodies with defined drug-to-antibody ratio (DAR) control and broad payload compatibility.
Accelerates Early Discovery
- Native IgG antibodies can be used directly without antibody engineering, enabling faster evaluation and reducing development complexity.
- Site-specific chemical conjugation eliminates the need for enzymatic modification, simplifying workflows and supporting cost-effective process development.
- Broad compatibility with antibodies and diverse payloads enables efficient screening, optimization, and scale-up across multiple bioconjugate modalities
Precise, Reproducible Conjugation
- AJICAP™ enables site-specific payload attachment with precise drug-to-antibody ratio (DAR) control, producing highly homogeneous antibody conjugates.
- Defined conjugation sites improve product consistency, reproducibility, and analytical characterization throughout development.
- The platform supports multiple conjugation strategies, including homogeneous DAR1 as well as higher DAR and dual-payload configurations, depending on program requirements
Robust Manufacturing & Payload Compatibility
- Compatible with a wide range of payloads, including cytotoxic small molecules, peptides, oligonucleotides, and nanoparticle conjugates.
- Hydrophilic linker strategies can reduce hydrophobicity, improve plasma stability, and minimize payload detachment during circulation.
- A straightforward chemical conjugation process, without antibody engineering or enzymatic steps, simplifies scale-up and manufacturing while minimizing or avoiding column purification.
Proven Capability and Integrated Approach
AJICAP™ has been applied across multiple bioconjugate modalities, including ADCs, degraders, peptides, oligonucleotide and LNP conjugates. Several AJICAP™-enabled programs have progressed into clinical studies, demonstrating its practical value in real-world development.
10+
under license
5+
INDs
2
Global manufacturing partners
Development and Manufacturing Support
Feasibility Studies & Candidate Selection
Feasibility studies and sample preparation using AJICAP™ enable rapid screening of antibodies, payloads, conjugation conditions, and drug-to-antibody ratio (DAR) to identify optimal conjugate designs.
Process Development & Optimization
We support antibody conjugation process development and optimization to establish reproducible, scalable processes using AJICAP™ technology, backed by in-house analytical characterization.
Technology Transfer & Manufacturing Support
For programs advancing to manufacturing, we coordinate technology transfer with qualified global CDMO partners while continuing to provide AJICAP™ technical expertise. Customers retain ownership of their product-specific manufacturing processes and intellectual property.
AJICAP™ solves the hardest ADC manufacturing & conjugation problems
Precise DAR
AJICAP™ enables precise DAR control by introducing a defined conjugation site on the Fc region. While homogeneous DAR2 is commonly achieved, the technology can also support alternative DAR formats, including DAR1, DAR4, dual-payload conjugates, and higher DAR configurations, depending on the overall conjugation design.
Minimal Payload Loss
The conjugation chemistry is compatible with various linker-payload designs. In particular, hydrophilic linker strategies, including the use of AJICAP™ linkers, can be applied to reduce hydrophobicity and improve plasma stability, thereby minimizing payload detachment during circulation.
Robust Manufacturing
The AJICAP™ process is robust and straightforward, without requiring antibody engineering or enzymatic steps. In addition, the process can be designed to minimize or avoid column purification, simplifying scale-up and manufacturing.
Bring Simplicity and Precision to ADC Development
Frequently Asked Questions
What is AJICAP™ and how does site-specific conjugation differ from other approaches?
AJICAP™ is a site-specific conjugation technology for native antibodies that enables controlled modification at defined sites on the Fc region.
Unlike conventional stochastic conjugation, which produces a mixture of species with broad DAR distribution, AJICAP™ generates highly homogeneous ADCs with precise DAR control. Compared with other site-specific approaches, AJICAP™ does not require antibody engineering or enzymatic steps, simplifying process development and improving reproducibility.
What DAR values can you achieve with AJICAP™ conjugation?
AJICAP™ enables precise and reproducible DAR control with a tight distribution.
Homogeneous DAR2 is most commonly achieved. In addition, alternative formats such as DAR1, DAR4, dual-payload conjugates, and higher DAR configurations (e.g., DAR 8,10,12) can be supported depending on the conjugation design.
In particular, selective DAR1 is a unique capability of AJICAP™, as only a limited number of conjugation technologies can reliably generate homogeneous DAR1 ADCs.
Overall, AJICAP™ provides flexible DAR design with high homogeneity compared with stochastic conjugation.
Do you offer GMP-grade ADC manufacturing for clinical trials?
We do not directly provide GMP manufacturing for ADCs and other bioconjugates in-house; however, for customers requiring clinical-grade production, we work with qualified global CDMO partners for GMP production. Our team supports process development and technology transfer to enable efficient transition to GMP manufacturing.
This flexible approach allows customers to select manufacturing options that best fit their development strategy.
What linker-payload combinations can you work with?
AJICAP™ is compatible with a wide range of linker-payload designs, including auristatins (e.g., MMAE), maytansinoids, topoisomerase I inhibitors (e.g., camptothecin derivatives such as DXd/exatecan), and PBDs.
The AJICAP™ technology can also support customer-original payloads and can be applied to other bioconjugates, such as peptide and oligonucleotide conjugates, depending on the overall conjugation design.
Can you support both the antibody and the linker-payload, or do we supply them?
Customers typically provide the antibody and linker-payload components.
Our team supports AJICAP™ conjugation process development and analytical characterization, and can provide guidance on linker-payload selection.
For commonly used payload classes in combination with AJICAP™ linkers, material supply from internal inventory may also be available.
For customers requiring manufacturing, qualified CDMO partners can be introduced, while allowing flexibility in material sourcing and development strategy.
What engagement models are available — fee-for-service, development partnership, or licensing?
AJICAP™ is offered through flexible engagement models, including fee-for-service evaluation, development support, and technology licensing. AJICAP™ technology is typically provided under a licensing model, allowing customers to integrate the platform into their own development and manufacturing workflows.